NASDAQ · CLDX
Celldex Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CLDX: Nov 9, 2026
Celldex Therapeutics, Inc. is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.02. The reported EPS for the same quarter last year was $-1.01.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.02 | $-0.96 | $-1.05 | 4 |
| Dec 2026 | $-1.04 | $-0.97 | $-1.09 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- Zacks · Sep 23, 8:37 AM EDTThe Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteFour biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
- MarketBeat · Sep 22, 12:02 PM EDTCelldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable ResponsesCelldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose
- Zacks · Sep 22, 10:51 AM EDT4 Biotech Stocks With Key Clinical Readouts Expected This FallKOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
- RTTNews · Sep 22, 10:46 AM EDTCelldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down(RTTNews) – Celldex (CLDX) reported positive topline results from two Phase 3 studies of Barzolvolimab, with the treatment meeting the primary endpoint and all key secondary endpoints in patients with chronic spontaneous urticaria, also known as chronic hives.
- RTTNews · Sep 22, 7:47 AM EDTCelldex Reports Positive Phase 3 Results For Barzolvolimab In CSU(RTTNews) – Celldex Therapeutics, Inc. (CLDX) Tuesday reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamine
- RTTNews · Aug 11, 4:05 AM EDTBiotech Stocks At 52-Week Highs – SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSX(RTTNews) – The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials.
- Zacks · Aug 6, 7:10 PM EDTCelldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue EstimatesCelldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 24, 11:02 AM EDTWeekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data(RTTNews) – This week, the biotech sector was marked by FDA and EU approvals, strategic acquisitions, and a major workforce restructuring. Clinical trial updates delivered both breakthroughs and setbacks across oncology, obesity, and dermatology, underscoring the sector's volatil
- Zacks · Jul 24, 9:40 AM EDTAre Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
- MarketBeat · Jul 22, 6:02 AM EDTCelldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 MissCelldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria
- RTTNews · Jul 22, 2:31 AM EDTCelldex's Barzolvolimab Fails To Meet Key Goals In Phase 2 Study For Prurigo Nodularis; Stock Down(RTTNews) – Celldex (CLDX) reported topline results from the Phase 2 study of Barzolvolimab in Prurigo Nodularis or PN, indicating that the study did not meet the primary endpoint and key secondary endpoints. Following the results, Celldex will discontinue the Phase 2 study in PN
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Celldex Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.